Skip to main content
OpenTrials
Completed

NCT Number: NCT02188589

Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse

To evaluate the safety and feasibility of the INEX Nasal Implant in subjects with moderate to severe nasal valve collapse.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde am Klinikum der LMU

Munich, 81377, Germany

About this study

This study is a multicenter, nonrandomized, prospective exploratory study of the INEX Nasal Implant. The purpose of this study is to evaluate the safety and feasibility of the INEX Nasal Implant in subjects with moderate to severe nasal valve collapse.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Eligible participants are:

  • Adult patients seeking treatment for nasal obstruction on one or both sides of the nose who are willing to undergo an office-based or intraoperative nasal implant procedure in lieu of alternative treatments (ie, surgical repair or use of an external dilator).
  • Nasal valve collapse (NVC) must be a primary or significant contributor to the subject's nasal obstruction based on clinical presentation, physical examination and nasal endoscopy.
  • Baseline Nasal Obstruction Symptom Evaluation (NOSE) score must be ≥55.

Participants are excluded for the following:

  • Surgical or non-surgical treatment of the nasal valve or rhinoplasty within 12 months before enrollment.
  • Septoplasty, inferior turbinate reduction, or other surgical nasal procedures within 6 months before enrollment.
  • Recurrent nasal infections.
  • Use of intranasal steroids within 2 weeks preimplant and 2 weeks post implantation.
  • Presence of a permanent implant, dilator, or uses an external device in the nasal area.
  • Cancerous or precancerous lesions and/or radiation exposure in the treatment area or chemotherapy within 24 months of the study.
  • Significant bleeding disorders.
  • Significant systemic diseases.
  • Currently using nasal oxygen or continuous positive airway pressure (CPAP).

Treatment and study plan

INEX nasal implant

Device

Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)

Primary outcomes

  1. Implant-related Adverse Events

    Time frame: 6 months

    Implant-related adverse events (such as implant retrievals, procedure-related hematoma/inflammation)

Secondary outcomes

  1. Breathing Capacity (NOSE Scores)

    Time frame: At baseline and at 6, 12, and 24 months post implant

    Nasal breathing capacity was assessed using the validated Nasal Obstruction Symptom Evaluation (NOSE) questionnaire. The NOSE score uses a 0-100 point scale to capture severity of nasal symptoms (congestion, obstruction, trouble breathing, sleeping, and exercise), with higher scores indicating more severe symptoms than lower scores. NOSE severity classes are defined as Mild (5-25), Moderate (30-50), Severe (55-75), and Extreme (80-100).

  2. NOSE Responder Rate

    Time frame: At 6, 12, and 24 months post implant

    Percent of participants meeting responder criteria. Responders are defined as participants with a reduction from baseline in 1 or more Nasal Obstruction Symptom Evaluation Score (NOSE) severity class or a 20% reduction in the NOSE score.

Sponsors and collaborators

Lead sponsor

Spirox, Inc.

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2017
First posted
Jul 11, 2014
Registry last updated
Mar 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.